AR005277A1 - Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. - Google Patents

Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.

Info

Publication number
AR005277A1
AR005277A1 ARP960105894A ARP960105894A AR005277A1 AR 005277 A1 AR005277 A1 AR 005277A1 AR P960105894 A ARP960105894 A AR P960105894A AR P960105894 A ARP960105894 A AR P960105894A AR 005277 A1 AR005277 A1 AR 005277A1
Authority
AR
Argentina
Prior art keywords
alkyl
derivatives
substituted
alkyloxy
hydroxy
Prior art date
Application number
ARP960105894A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR005277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR005277A1 publication Critical patent/AR005277A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Derivados de piperidina 1-(piperidinil 1,2-disustituido)-4-sustituidos de la fórmula (I), las formas de N-óxido, las sales de adición farmacéuticamenteaceptables y las formas estereoquímicamente isoméricas de los mismos en los cuales n es 0, 1o 2; m es 1 o 2, siempre que si m es 2, n sea 1; p es 0, 1 o2; Q es O o NR3; X es un enlace covalente o un radical bivalente de la fórmula -O, -S-, NR3-; R1 es Ar1 alquilo C1-6 o di(Ar1)alquilo C1-6, donde cada grupoalquilo C1-C6 está optativamentesustituido con hidroxi, alquiloxi C1-C4, oxo o un sustituyente oxo cetalizado de la fórmula -O-CH2-CH2-O o -O-CH2-CH2-CH2-O-; R2 es Ar2, Ar2 alquilo C1-6, Het o Het alquilo C1-6; R3 es hidrógeno o alquilo C1-C6; R4 es hidrógeno, alquilo C1-C4, alquiloxi C1-C4 alquilo C1-C4,hidroxi-alquilo C1-C4, carboxilo, alquiloxicarbonilo C1-C4 o Ar3; R5 es hidrógeno, hidroxi, Ar3, Ar3 alcoxi C1-6, di(Ar3)alquiloxi C1-6, Ar3 alquiltioC1-6, Ar3 alquilsulfoxi C1-6, di(Ar3)alquilsulfoxi C1-6, Ar3alquilsulfonilo C1-6, di(Ar3)alquilsulfonilo C1-6; -NR7R8, alquilo C1-6 sustituido con -NR7R8,o un radical de la fórmula (a-1) o (a-2); R4 y R5 también pueden tomados juntos; R6 es hidrógeno, hidroxi, alquiloxi C1-6, alquilo C1-C6 o Ar3 alquiloC1-6; Ar1, Ar2 y Ar3 son fenilo o fenilo sustituido; Ar2 es igualmente naftalenilo; y Het es un heterocíclico monocíclico o bicíclico optativamentesustituido; como antagonistas de la sustancia P; su proceso de preparación, composiciones que los contienen, su proceso de preparación y su uso comomedicamento.
ARP960105894A 1995-12-27 1996-12-26 Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. AR005277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203651 1995-12-27

Publications (1)

Publication Number Publication Date
AR005277A1 true AR005277A1 (es) 1999-04-28

Family

ID=8221023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105894A AR005277A1 (es) 1995-12-27 1996-12-26 Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.

Country Status (29)

Country Link
US (2) US6169097B1 (es)
EP (1) EP0855999B1 (es)
JP (1) JP4039691B2 (es)
KR (1) KR100493574B1 (es)
CN (1) CN1131854C (es)
AR (1) AR005277A1 (es)
AT (1) ATE206397T1 (es)
AU (1) AU707037B2 (es)
BR (1) BR9612334A (es)
CA (1) CA2238818C (es)
CZ (1) CZ296316B6 (es)
DE (1) DE69615700T2 (es)
DK (1) DK0855999T3 (es)
EA (1) EA001559B1 (es)
ES (1) ES2164939T3 (es)
HK (1) HK1011205A1 (es)
HU (1) HU228128B1 (es)
IL (1) IL124640A (es)
MY (1) MY117557A (es)
NO (1) NO310913B1 (es)
NZ (1) NZ325843A (es)
PL (1) PL192397B1 (es)
PT (1) PT855999E (es)
SI (1) SI0855999T1 (es)
SK (1) SK283555B6 (es)
TR (1) TR199801211T2 (es)
TW (1) TW531537B (es)
WO (1) WO1997024324A1 (es)
ZA (1) ZA9610885B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
WO1999032486A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
BR9913201A (pt) 1998-08-25 2001-05-08 Novartis Ag Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica
AU2056800A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
KR20020009570A (ko) * 1999-03-05 2002-02-01 도리이 신이찌로 니코틴성 아세틸콜린 α4β2 수용체의 활성화 작용을 가진헤테로시클릭 화합물
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
DE60013464T2 (de) * 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
CA2413245A1 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
PL364560A1 (en) 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
EP1386920A4 (en) * 2001-04-20 2005-09-14 Banyu Pharma Co Ltd DERIVATIVES OF BENZIMIDAZOLONE
ES2258642T3 (es) * 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
US7279490B2 (en) 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JPWO2006054513A1 (ja) * 2004-11-19 2008-05-29 キッセイ薬品工業株式会社 神経因性疼痛の予防又は治療剤
CA2598530C (en) * 2005-03-03 2014-12-16 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
EP1912941B1 (en) 2005-07-21 2012-11-14 AstraZeneca AB Piperidine derivatives
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
EA200970706A1 (ru) 2007-01-24 2010-02-26 Глэксо Груп Лимитед Новые фармацевтические композиции
EA020548B1 (ru) * 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
CA2753205A1 (en) * 2009-02-19 2010-08-26 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
ES2524829T3 (es) 2009-12-17 2014-12-12 Boehringer Ingelheim International Gmbh Nuevos antagonistas del receptor CCR2 y usos de los mismos
ES2561674T3 (es) * 2010-03-23 2016-02-29 Glaxosmithkline Llc Antagonistas de TRPV4
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
JP6917910B2 (ja) 2015-07-02 2021-08-11 セントレクシオン セラピューティクス コーポレイション （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
SG11202007164UA (en) * 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW231291B (es) * 1992-01-09 1994-10-01 Janssen Pharmaceutica Nv
CA2171850A1 (en) 1994-07-15 1996-02-01 Kiyoaki Katano Novel compound having platelet aggregation inhibitor effect
EP0783490B1 (en) 1994-09-30 2002-02-06 Novartis AG 1-acyl-4-aliphatic aminopiperidine compounds
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives

Also Published As

Publication number Publication date
JP2000502690A (ja) 2000-03-07
PL327441A1 (en) 1998-12-07
NO982404D0 (no) 1998-05-27
CN1206406A (zh) 1999-01-27
PT855999E (pt) 2002-03-28
IL124640A0 (en) 1998-12-06
CZ296316B6 (cs) 2006-02-15
DE69615700T2 (de) 2002-09-05
NO310913B1 (no) 2001-09-17
DE69615700D1 (de) 2001-11-08
NZ325843A (en) 1999-05-28
IL124640A (en) 2002-05-23
SK83198A3 (en) 1999-02-11
AU707037B2 (en) 1999-07-01
HK1011205A1 (en) 1999-07-09
MY117557A (en) 2004-07-31
CN1131854C (zh) 2003-12-24
EA199800604A1 (ru) 1998-12-24
AU1308497A (en) 1997-07-28
SI0855999T1 (en) 2001-12-31
CA2238818A1 (en) 1997-07-10
TW531537B (en) 2003-05-11
DK0855999T3 (da) 2002-01-21
CA2238818C (en) 2006-10-17
KR19990076716A (ko) 1999-10-15
ZA9610885B (en) 1998-06-23
SK283555B6 (sk) 2003-09-11
WO1997024324A1 (en) 1997-07-10
NO982404L (no) 1998-08-19
US6346540B1 (en) 2002-02-12
BR9612334A (pt) 1999-03-02
PL192397B1 (pl) 2006-10-31
HUP9904125A3 (en) 2002-03-28
EP0855999A1 (en) 1998-08-05
JP4039691B2 (ja) 2008-01-30
US6169097B1 (en) 2001-01-02
ATE206397T1 (de) 2001-10-15
KR100493574B1 (ko) 2006-05-26
EA001559B1 (ru) 2001-04-23
TR199801211T2 (xx) 1998-09-21
EP0855999B1 (en) 2001-10-04
HU228128B1 (hu) 2012-12-28
ES2164939T3 (es) 2002-03-01
HUP9904125A2 (hu) 2000-06-28
CZ186498A3 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
AR005277A1 (es) Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.
MX9803407A (es) Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos.
AR051093A1 (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
AR002241A1 (es) Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo.
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
AR018169A1 (es) Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
AR013361A1 (es) BENZAMIDAS BICíCLICAS DE DERIVADOS 3-o4-SUBSTITUíDOS DE 4-(AMINOMETIL)- PIPERIDINAS, PROCEDIMIENTO PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTO INTERMEDIARIO Y PROCEDIMIENTO PARA SU PREPARACIoN.
MY117680A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives
AR012102A1 (es) Derivados de 2-(iminometil)amino-fenilo, su preparacion, uso de los mismos para la fabricacion de medicamentos y composiciones farmaceuticas que los contienen.
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
AR033996A1 (es) Una 7-oxo-piridopirimidina, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, un proceso para producir una pirimidina, un proceso para producir una piridopirimidina, y compuestos preparados mediante dichos procesos
AR011117A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas, composiciones farmaceuticas que las contienen, compuestos intermediarios para producirlas y uso de los compuestos en la preparacion de medicamentos.
AR021662A1 (es) Derivados de la piperazina, proceso para prepararlos. las composiciones farmaceuticas que los contienen y la utilizacion de las mismas como medicamentoso para la preparacion de medicamentos
AR005279A1 (es) Derivados 1-(piperidinil 1,2-disustituido)-4-(bencimidazolil e imidazopiridinil)-piperidina, proceso para su preparacion, composicion farmaceutica, y proceso para preparar dicha composicion
DK0478446T3 (da) Heterocykliske alkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
MX9302957A (es) Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR046170A1 (es) Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
DK0465369T3 (da) N-substituerede derivater af alpha-mercaptoalkylaminer, deres fremstilling og anvendelse som lægemidler, farmaceutiske præparater med indhold deraf samt mellemprodukter
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
AR008826A1 (es) Derivados de xanteno y acridina, procedimiento para su preparacion y medicamentos que los contienen